Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
IGF1RES
MCID: INS024
MIFTS: 76

Insulin-Like Growth Factor I (IGF1RES)

Categories: Ear diseases, Endocrine diseases, Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Insulin-Like Growth Factor I

About this section

MalaCards integrated aliases for Insulin-Like Growth Factor I:

Name: Insulin-Like Growth Factor I 57
Insulin-Like Growth Factor I Deficiency 57 53 75 37 29 6 73
Igf1 Deficiency 57 53 75 55
Growth Retardation with Deafness and Mental Retardation Due to Igf1 Deficiency 57 13 40
Insulin-Like Growth Factor I, Resistance to 57 13 73
Insulin-Like Growth Factor 1 Resistance to 53 29 6
Growth Retardation with Sensorineural Deafness and Mental Retardation 57 53
Growth Delay Due to Insulin-Like Growth Factor I Resistance 59 37
Igf-I Resistance 57 55
Igf1res 57 75
Growth Delay Due to Insulin-Like Growth Factor Type 1 Deficiency 59
Growth Delay-Deafness- Intellectual Disability Syndrome 59
Primary Insulin-Like Growth Factor Deficiency 59
Insulin-Like Growth Factor 1, Resistance to 40
Resistance to Insulin-Like Growth Factor I 75
Somatomedin, End-Organ Insensitivity to 57
Insulin-Like Growth Factor 1 Resistance 75
Somatomedin End-Organ Insensitivity to 53
End-Organ Insensitivity to Somatomedin 75
Somatomedin-C, Resistance to 57
Somatomedin-C Resistance to 53
Resistance to Somatomedin-C 75
Resistance to Igf-1 59
Igf-1 Resistance 53
Igf-1 Deficiency 59
Igf1 Resistance 75
Somatomedin-C 57

Characteristics:

Orphanet epidemiological data:

59
growth delay due to insulin-like growth factor type 1 deficiency
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Infancy,Neonatal;
growth delay due to insulin-like growth factor i resistance
Inheritance: Autosomal dominant,Autosomal recessive; Age of onset: Infancy,Neonatal;

OMIM:

57
Inheritance:
autosomal recessive
autosomal dominant

Miscellaneous:
onset in utero
dominant and recessive patients have iugr, short stature, and microcephaly
heterozygous relatives of some biallelic patients appear to be unaffected


HPO:

32
insulin-like growth factor i:
Onset and clinical course congenital onset
Inheritance autosomal recessive inheritance autosomal dominant inheritance

insulin-like growth factor i deficiency:
Onset and clinical course congenital onset
Inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Endocrine diseases Neuronal diseases Ear diseases Mental diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare endocrine diseases


Sources

Summaries for Insulin-Like Growth Factor I

About this section
NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 73273Disease definitionGrowth delay due to IGF-I resistance is characterised by variable intrauterine and postnatal growth retardation and elevated serum IGF-I levels. Addition features include variable degrees of intellectual deficit, microcephaly and dysmorphism (broad nasal bridge and tip, smooth philtrum, thin upper and everted lower lips, short fingers, clinodactyly, wide-set nipples and pectus excavatum).EpidemiologyPrevalence is unknown.EtiologyIGF-I resistance may be caused by a variety of genetic defects: ring chromosome 15, distal heterozygous 15q deletions encompassing the IGF1R gene (15q26.3), or IGF1R gene mutations. Intellectual deficit is pronounced in patients with ring chromosome 15 but varies depending on the size of the deletion and on the functions of other deleted genes in patients with 15q deletions. Partial IGF-I insensitivity due to IGF1R haploinsufficiency has been reported in one patient with a small deletion encompassing one allele of the IGF1R gene and was characterised by small size for gestational age, persistent growth failure that improved considerably with GH therapy, and the absence of intellectual deficit. IGF1R mutations have been described in six patients so far and were associated with variable growth delay and degrees of intellectual deficit.Diagnostic methodsDiagnosis relies on karyotyping for detection of ring chromosome 15, detection of small deletions encompassing IGF1R and detection of IGF1R mutations by sequence variation screening methods or by direct sequencing of the 21 IGF1R exons and their intron-exon junctions.Differential diagnosisThe differential diagnosis should include bio-inactive IGF-I resulting in IGF-I deficiency (see this term). Measurement of IGF-I levels can be used for diagnosis but circulating levels of IGF-I may vary over time for the same patient and may not be elevated in case of poor nutritional status.Antenatal diagnosisPrenatal diagnosis has not been reported and is complicated by the variable expressivity (even within the same family) of some of the reported mutations, especially in terms of their impact on intellectual development.Genetic counselingIn all but one of these patients, the mutations were heterozygous and transmitted as an autosomal dominanttrait. Affected families should be offered genetic counselling and informed of a 50% risk of recurrence for dominant inheritance and of a 25% risk of recurrence for recessive transmission.Management and treatmentManagement involves nutritional and developmental support. Although deafness has not yet been reported in patients with IGF-I resistance, it is present in some patients with IGF-I deficiency (caused by mutations in the gene encoding the IGF1R ligand, IGFI). As a result, screening for deafness should be proposed for all patients with IGF-I resistance. Some patients with IGF-I resistance show increased growth velocity with recombinant GH therapy while others show no response.PrognosisPrognosis varies depending on the underlying molecular anomaly.Visit the Orphanet disease page for more resources.

MalaCards based summary : Insulin-Like Growth Factor I, also known as insulin-like growth factor i deficiency, is related to laron syndrome and acid-labile subunit deficiency, and has symptoms including agitation An important gene associated with Insulin-Like Growth Factor I is IGF1 (Insulin Like Growth Factor 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Oocyte meiosis. The drugs Estradiol and Mecasermin have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and prostate, and related phenotypes are pectus excavatum and clinodactyly

OMIM : 57 Patients with mutations in the receptor for insulin-like growth factor I show intrauterine growth retardation and postnatal growth failure, resulting in short stature and microcephaly. Other features may include delayed bone age, developmental delay, and dysmorphic features. (270450)

UniProtKB/Swiss-Prot : 75 Insulin-like growth factor 1 resistance: A disorder characterized by intrauterine growth retardation, poor postnatal growth and increased plasma IGF1 levels. Insulin-like growth factor I deficiency: Autosomal recessive disorder characterized by growth retardation, sensorineural deafness and mental retardation.

Wikipedia : 76 Insulin-like growth factor 1 (IGF-1), also called somatomedin C, is a protein that in humans is encoded... more...

Sources

Related Diseases for Insulin-Like Growth Factor I

About this section

Diseases related to Insulin-Like Growth Factor I via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 367)
# Related Disease Score Top Affiliating Genes
1 laron syndrome 33.1 GH1 GHR IGF1 IGF2 IGFBP3
2 acid-labile subunit deficiency 32.9 IGF1 IGF2 IGFBP3
3 growth hormone deficiency 31.5 GH1 IGF1 IGFBP3
4 acromegaly 31.3 GH1 GHR IGF1 IGF2 IGFBP1 IGFBP3
5 polycystic ovary syndrome 31.0 IGF1 IGFBP1 INS INSR IRS1
6 diabetes mellitus 30.9 AKT1 AKT2 IGF1 IGFBP1 INS INSR
7 osteoporosis 30.8 GH1 GHR IGF1 IGFBP3 IGFBP4 IGFBP5
8 anorexia nervosa 30.8 GH1 GHR IGF1 IGFBP1 IGFBP2 IGFBP3
9 hyperglycemia 30.7 IGF1 INS INSR IRS1
10 prostate cancer 30.6 AKT1 AKT2 IGF1 IGF1R IGF2 IGFBP2
11 glucose intolerance 30.6 IGF1 IGFBP1 INS INSR IRS1
12 hyperandrogenism 30.6 IGF1 IGFBP1 INS INSR
13 isolated growth hormone deficiency 30.6 GH1 GHR IGF1
14 turner syndrome 30.6 GH1 GHR IGF1 IGFBP1 IGFBP3
15 ovarian disease 30.6 AKT1 IGF1 IGF1R IGFBP1 IGFBP2 INS
16 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 30.5 IGF1 IGFBP3 INS INSR
17 craniopharyngioma 30.5 GH1 IGF1 INS
18 endometrial cancer 30.4 AKT1 AKT2 IGF1 IGF1R IGFBP1 INS
19 silver-russell syndrome 30.4 GH1 IGF1 IGF2 IGFBP1 IGFBP3
20 secondary adrenal insufficiency 30.4 IGF1 IGFBP3 INS
21 donohue syndrome 30.3 IGF1 IGF1R INS INSR
22 nutritional deficiency disease 30.3 IGF1 IGFBP1 IGFBP3
23 prader-willi syndrome 30.3 GH1 GHR IGF1 IGF2 IGFBP1 IGFBP3
24 hypopituitarism 30.3 GH1 IGF1 IGFBP3 INS
25 breast cancer 30.3 AKT1 AKT2 IGF1 IGF1R IGF2 IGFBP3
26 breast disease 30.2 IGF1 IGF2 IGFBP1 IGFBP3
27 chronic kidney failure 30.2 IGF1 IGFBP1 IGFBP3 INS
28 microvascular complications of diabetes 1 30.2 IGF1 IGFBP3 INS
29 fetal macrosomia 30.2 IGF1 IGF2 IGFBP3 INS INSR
30 hyperinsulinism 30.1 GH1 IGF1 IGFBP1 IGFBP3 INS INSR
31 diabetes mellitus, noninsulin-dependent 30.1 AKT1 AKT2 GH1 IGF1 IGF1R IGF2
32 diabetes mellitus, insulin-dependent 30.1 GHR IGF1 IGF2 IGFBP1 IGFBP2 IGFBP3
33 ewing sarcoma 30.0 AKT1 IGF1 IGF1R IGF2 IGFBP3 INS
34 growth hormone insensitivity with immunodeficiency 11.6
35 growth factors, combined defect of 11.5
36 kowarski syndrome 11.3
37 isolated growth hormone deficiency, type iv 11.3
38 colorectal cancer 10.6
39 neuroblastoma 10.6
40 aging 10.6
41 lung cancer 10.5
42 pancreatic cancer 10.5
43 ovarian cancer 10.5
44 hypoxia 10.5
45 dengue hemorrhagic fever 10.4
46 polycystic kidney disease 10.4
47 hepatosplenic t-cell lymphoma 10.4
48 alzheimer disease 10.4
49 liver cirrhosis 10.4
50 liver disease 10.4

Graphical network of the top 20 diseases related to Insulin-Like Growth Factor I:



Diseases related to Insulin-Like Growth Factor I
Sources

Symptoms & Phenotypes for Insulin-Like Growth Factor I

About this section

Symptoms via clinical synopsis from OMIM:

57
Skeletal Hands:
clinodactyly
short fingers
small hands

Head And Neck Head:
microcephaly

Growth Other:
intrauterine growth retardation
poor growth

Head And Neck Face:
triangular face
long, smooth philtrum
facial dysmorphism (in some patients)
receding hairline
progeroid appearance (in some recessive patients)
more
Skeletal:
delayed bone age

Growth Weight:
low weight

Chest External Features:
pectus excavatum (rare)

Head And Neck Eyes:
deep-set eyes (recessive)
strabismus (recessive)
synophrys (recessive)
arched eyebrows (recessive)
upslanting palpebral fissures (recessive)
more
Head And Neck Neck:
pterygium colli (recessive)

Cardiovascular Vascular:
narrowing of pulmonary branch arteries (recessive)
continuation of inferior vena cava to azygos vein (recessive)

Skin Nails Hair Skin:
axillary acanthosis nigricans (recessive)

Muscle Soft Tissue:
reduced subcutaneous fat (recessive)
truncal obesity (recessive)
lipodystrophy (recessive)

Endocrine Features:
elevated baseline insulin (recessive)
diabetes mellitus, type 2 (in some heterozygous adults)
diabetes mellitus, type 1 (in 1 recessive adolescent patient)

Neurologic Central Nervous System:
global developmental delay
delayed motor development
mental retardation
speech delay
developmental delay, mild
more
Growth Height:
short stature

Neurologic Behavioral Psychiatric Manifestations:
agitation
anxious affect
obsessive tendencies

Head And Neck Nose:
broad nasal bridge

Head And Neck Mouth:
thin upper lip
fleshy lower lip
high-arched palate (recessive)
small mouth (recessive)

Skeletal Feet:
small feet
sandal gap (recessive)

Head And Neck Ears:
low-set ears (recessive)

Head And Neck Teeth:
delayed eruption of dentition (recessive)
small opalescent teeth (recessive)
brittle teeth (recessive)
eroded teeth (recessive)

Cardiovascular Heart:
patent foramen ovale (recessive)
atrial septal defect (recessive)
ventricular septal defect (recessive)

Chest Breasts:
widely spaced nipples (rare)

Skin Nails Hair Hair:
sparse scalp hair (recessive)

Voice:
high-pitched voice (recessive)

Laboratory Abnormalities:
increased serum insulin-like growth factor-1 (igf1, )
increased or normal serum growth hormone (gh, )


Clinical features from OMIM:

270450 608747

Human phenotypes related to Insulin-Like Growth Factor I:

59 32 (show top 50) (show all 82)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pectus excavatum 59 32 frequent (33%) Frequent (79-30%) HP:0000767
2 clinodactyly 59 32 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0030084
3 ptosis 59 32 Occasional (29-5%) HP:0000508
4 intellectual disability 59 32 frequent (33%) Very frequent (99-80%),Frequent (79-30%) HP:0001249
5 failure to thrive 59 32 hallmark (90%) Very frequent (99-80%) HP:0001508
6 delayed skeletal maturation 59 32 frequent (33%) Frequent (79-30%),Very frequent (99-80%) HP:0002750
7 wide nasal bridge 59 32 frequent (33%) Frequent (79-30%) HP:0000431
8 abnormal facial shape 59 32 hallmark (90%) Very frequent (99-80%) HP:0001999
9 microcephaly 59 32 hallmark (90%) Very frequent (99-80%),Frequent (79-30%) HP:0000252
10 smooth philtrum 59 32 frequent (33%) Frequent (79-30%) HP:0000319
11 sensorineural hearing impairment 59 32 Very frequent (99-80%) HP:0000407
12 short stature 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0004322
13 intellectual disability, mild 59 32 hallmark (90%) Very frequent (99-80%) HP:0001256
14 osteoporosis 59 32 frequent (33%) Frequent (79-30%) HP:0000939
15 prominent forehead 59 32 occasional (7.5%) Occasional (29-5%) HP:0011220
16 hypoglycemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001943
17 micrognathia 59 32 frequent (33%) Frequent (79-30%) HP:0000347
18 delayed eruption of teeth 59 32 frequent (33%) Frequent (79-30%) HP:0000684
19 short palm 59 32 frequent (33%) Frequent (79-30%) HP:0004279
20 concave nasal ridge 59 32 occasional (7.5%) Occasional (29-5%) HP:0011120
21 everted lower lip vermilion 59 32 frequent (33%) Frequent (79-30%) HP:0000232
22 attention deficit hyperactivity disorder 59 32 hallmark (90%) Very frequent (99-80%) HP:0007018
23 intrauterine growth retardation 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0001511
24 wide intermamillary distance 59 32 frequent (33%) Frequent (79-30%) HP:0006610
25 low posterior hairline 59 32 occasional (7.5%) Occasional (29-5%) HP:0002162
26 myopia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000545
27 motor delay 59 32 occasional (7.5%) Occasional (29-5%),Frequent (79-30%) HP:0001270
28 hypogonadism 59 32 frequent (33%) Frequent (79-30%) HP:0000135
29 clinodactyly of the 5th finger 59 32 frequent (33%) Frequent (79-30%) HP:0004209
30 broad nasal tip 59 32 frequent (33%) Frequent (79-30%) HP:0000455
31 low anterior hairline 59 32 occasional (7.5%) Occasional (29-5%) HP:0000294
32 thin vermilion border 59 32 frequent (33%) Frequent (79-30%) HP:0000233
33 congenital sensorineural hearing impairment 59 32 hallmark (90%) Very frequent (99-80%) HP:0008527
34 truncal obesity 59 32 occasional (7.5%) Occasional (29-5%) HP:0001956
35 severe postnatal growth retardation 59 32 hallmark (90%) Very frequent (99-80%) HP:0008850
36 hyperactivity 59 32 Very frequent (99-80%) HP:0000752
37 single transverse palmar crease 59 32 occasional (7.5%) Occasional (29-5%) HP:0000954
38 insulin resistance 59 32 hallmark (90%) Very frequent (99-80%) HP:0000855
39 cafe-au-lait spot 59 32 occasional (7.5%) Occasional (29-5%) HP:0000957
40 severe intrauterine growth retardation 59 32 hallmark (90%) Very frequent (99-80%) HP:0008846
41 small for gestational age 59 32 hallmark (90%) Very frequent (99-80%) HP:0001518
42 small placenta 59 32 frequent (33%) Frequent (79-30%) HP:0006266
43 bilateral sensorineural hearing impairment 59 32 hallmark (90%) Very frequent (99-80%) HP:0008619
44 short attention span 59 32 Very frequent (99-80%) HP:0000736
45 neonatal hyperbilirubinemia 59 32 frequent (33%) Frequent (79-30%) HP:0003265
46 prelingual sensorineural hearing impairment 59 32 hallmark (90%) Very frequent (99-80%) HP:0000399
47 congenital bilateral ptosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0007911
48 high palate 32 HP:0000218
49 diabetes mellitus 32 HP:0000819
50 osteopenia 32 HP:0000938

UMLS symptoms related to Insulin-Like Growth Factor I:


agitation

GenomeRNAi Phenotypes related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

26 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.6 ITGB3
2 Decreased viability GR00221-A-1 10.6 AKT1 AKT2 IGF1R INSR IRS1
3 Decreased viability GR00221-A-2 10.6 AKT1 IGF1R INSR IRS1 ITGAV ITGB3
4 Decreased viability GR00221-A-3 10.6 AKT1 AKT2 IGF1R INSR
5 Decreased viability GR00221-A-4 10.6 AKT1 AKT2 INSR ITGB3
6 Decreased viability GR00301-A 10.6 AKT2 IGF1R
7 Decreased viability GR00342-S-2 10.6 IGF1R IRS1
8 Decreased viability GR00342-S-3 10.6 AKT2 IRS1
9 Decreased viability GR00381-A-1 10.6 ITGAV
10 Decreased viability GR00402-S-2 10.6 AKT1 AKT2 IGF1R INSR IRS1 ITGAV
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.19 GH1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 10.19 INSR
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.19 IGF1R
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.19 IGF1R
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-155 10.19 GH1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 10.19 INSR
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.19 AKT1 INSR
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.19 AKT2
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.19 INSR
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.19 AKT1 AKT2 GH1 IGF1R INSR
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.19 INSR
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.19 IGF1R
23 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 AKT2 IGF1R IRS1 ITGA6 ITGAV ITGB3
24 Increased cell death HMECs cells GR00103-A-0 9.5 IGF1R IGFBP4 IGFBP6 INS INSR IRS1
25 Increased cell viability after pRB stimulation GR00230-A-1 8.92 AKT1 AKT2 IGF1R INSR

MGI Mouse Phenotypes related to Insulin-Like Growth Factor I:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.41 AKT1 AKT2 GHR IGF1 IGF1R IGF2
2 cardiovascular system MP:0005385 10.4 AKT1 GHR IGF1 IGF1R IGF2 IGFBP2
3 cellular MP:0005384 10.39 AKT1 AKT2 GHR IGF1 IGF1R IGF2
4 endocrine/exocrine gland MP:0005379 10.39 AKT1 AKT2 GHR IGF1 IGF1R IGF2
5 homeostasis/metabolism MP:0005376 10.36 AKT1 AKT2 GHR IGF1 IGF1R IGF2
6 hematopoietic system MP:0005397 10.34 AKT1 AKT2 GHR IGF1 IGF1R IGF2
7 immune system MP:0005387 10.34 AKT1 AKT2 GHR IGF1 IGF1R IGF2
8 adipose tissue MP:0005375 10.33 AKT1 AKT2 GHR IGF1 IGF1R IGFBP3
9 muscle MP:0005369 10.25 AKT1 AKT2 GHR IGF1 IGF1R IGF2
10 liver/biliary system MP:0005370 10.21 AKT1 AKT2 GHR IGF1R IGF2 IGFBP1
11 integument MP:0010771 10.18 AKT1 AKT2 GHR IGF1 IGF1R IGF2
12 embryo MP:0005380 10.16 AKT1 GHR IGF1R IGF2 INS ITGA6
13 digestive/alimentary MP:0005381 10.11 IGF1R IGF2 INS INSR ITGA6 ITGAV
14 nervous system MP:0003631 10.06 AKT1 AKT2 GHR IGF1 IGF1R IGF2
15 limbs/digits/tail MP:0005371 10 GHR IGF1 IGF1R IGF2 IGFBP3 IRS1
16 renal/urinary system MP:0005367 9.96 GHR IGF1 IGF2 IGFBP2 IGFBP3 INS
17 neoplasm MP:0002006 9.91 AKT1 AKT2 IGF1 IGF1R ITGA6 ITGAV
18 reproductive system MP:0005389 9.81 AKT1 AKT2 GHR IGF1 IGF1R IGF2
19 respiratory system MP:0005388 9.61 AKT1 AKT2 IGF1 IGF1R IGF2 IGFBP3
20 skeleton MP:0005390 9.32 AKT1 AKT2 GHR IGF1 IGF1R IGF2
Sources

Drugs & Therapeutics for Insulin-Like Growth Factor I

About this section

Drugs for Insulin-Like Growth Factor I (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 570)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
2
Mecasermin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68562-41-4
3
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
4 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 979-32-8
5
Clonidine Approved Phase 4,Phase 2,Phase 3 4205-90-7 2803
6
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
7
Pasireotide Approved Phase 4,Phase 3,Phase 1,Phase 2 396091-73-9 9941444
8 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
9
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51110-01-1, 38916-34-6 53481605
10
Testosterone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-22-0 6013
11
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 7440-66-6
12
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
13
Anastrozole Approved, Investigational Phase 4,Phase 2,Not Applicable 120511-73-1 2187
14
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 329-65-7 838
15
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 51-43-4 5816
16
Tibolone Approved, Investigational Phase 4 5630-53-5
17
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
18
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
19
Fosinopril Approved Phase 4 98048-97-6 55891
20
Sodium oxybate Approved Phase 4 502-85-2 5360545
21
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
22
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2 302-25-0
23
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
24
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 5949-44-0
25
Methyltestosterone Approved Phase 4,Phase 2,Phase 3,Phase 1 58-18-4 6010
26
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2 2921-57-5
27
Testosterone enanthate Approved Phase 4,Phase 2,Phase 3,Phase 1 315-37-7 9416
28
Insulin Aspart Approved Phase 4 116094-23-6 16132418
29
Verapamil Approved Phase 4 52-53-9 2520
30
Liraglutide Approved Phase 4,Phase 2 204656-20-2 44147092
31
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
32
Ranibizumab Approved Phase 4 347396-82-1 459903
33
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 3 57-63-6 5991
34
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
35 tannic acid Approved Phase 4,Phase 2,Phase 3,Not Applicable
36
Insulin Detemir Approved Phase 4,Phase 3 169148-63-4 5311023
37
Citalopram Approved Phase 4 59729-33-8 2771
38
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
39
Letrozole Approved, Investigational Phase 4,Phase 2 112809-51-5 3902
40
Pravastatin Approved Phase 4 81093-37-0 54687
41
Norelgestromin Approved, Investigational Phase 4 53016-31-2 13752005
42
Desogestrel Approved Phase 4 54024-22-5 40973
43
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
44
Desflurane Approved Phase 4 57041-67-5 42113
45
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
46
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
47
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
48
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 53-43-0 5881
49
Prednisolone hemisuccinate Experimental Phase 4,Phase 2 2920-86-7
50 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 916)
# Name Status NCT ID Phase Drugs
1 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
2 Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Unknown status NCT01052623 Phase 4 Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
3 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
4 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
5 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
6 Pasireotide LAR and Pegvisomant Study in Acromegaly Unknown status NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
7 Effect of Growth Hormone in Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
8 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
9 Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Unknown status NCT02908958 Phase 4
10 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Unknown status NCT02976675 Phase 4
11 The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders Unknown status NCT02357472 Phase 4 dehydroepiandrosterone
12 Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With CVD. Completed NCT02092584 Phase 4
13 The Effect of Ophiocephalus Striatus Extract on Levels of IGF-1, Albumin, and MNA Score in Elderly With Malnutrition Completed NCT03065595 Phase 4
14 IGF1 Generation Test Completed NCT00145457 Phase 4
15 A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Completed NCT00212758 Phase 4 Nutropin AQ
16 Study to Compare the Effect of Hormone Replacement Therapy (HRT) on Breast and Cardiovascular Metabolic Markers in Postmenopausal Women Completed NCT00145522 Phase 4 17ß-Estradiol/Dydrogesterone;Tibolone
17 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
18 Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® Completed NCT00256126 Phase 4 Saizen;Saizen
19 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
20 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
21 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
22 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
23 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
24 Ultrasound Guided Octreotide LAR Injection in Acromegaly Completed NCT00552071 Phase 4 Octreotide LAR 30 MG Injection
25 Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01014338 Phase 4 Fosinopril
26 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
27 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
28 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4 Pegvisomant;Sandostatin LAR
29 Dehydroepiandrosterone (DHEA)Supplementation Pre-IVF(In Vitro Fertilization) Cycles Completed NCT02866253 Phase 4 DHEA
30 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes Completed NCT00345800 Phase 4 Sodium Oxybate (Xyrem)
31 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
32 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Completed NCT02311894 Phase 4 Somatropin
33 Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature Completed NCT00458263 Phase 4 Somatotropin growth hormone recombinant human
34 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years Completed NCT01066052 Phase 4 r-hGH
35 Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men Completed NCT00957801 Phase 4 Testosterone injection;Testosterone gel;Medrol
36 Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients Completed NCT01209403 Phase 4 Glucose-infusion;Glucose-insulin infusion
37 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4 somatropin;placebo
38 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
39 The Health Influences of Puberty (HIP) Study Completed NCT01775813 Phase 4 Metformin
40 Treatment of Hypoglycemia Following Gastric Bypass Surgery Completed NCT02527993 Phase 4 Glucobay (acarbose);Januvia (sitagliptin);Verapamil HEXAL (verapamil);Victoza (liraglutide);Signifor (pasireotide)
41 Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment. Completed NCT01972789 Phase 4 Ranibizumab
42 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
43 Cognitive Dysfunction in MDD Patients Recruiting NCT03187093 Phase 4 Vortioxetine;Escitalopram
44 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Recruiting NCT03249480 Phase 4
45 Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole Recruiting NCT02137538 Phase 4 Letrozole;Anastrozole
46 Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children Recruiting NCT03290235 Phase 4 PEG-somatropin
47 The Statins on Glucose Homeostasis in Subjects With Impaired Fasting Glucose Recruiting NCT01816997 Phase 4 Pravastatin;Rosuvastatin;Control
48 Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis Active, not recruiting NCT02367833 Phase 4 Combined Oral Contraceptive;Transdermal Contraceptive;Contraceptive Vaginal Ring
49 Assessing the Impact of Contraceptives on Bone Health Using 41Ca Active, not recruiting NCT02367846 Phase 4 Combined Oral Contraceptive (COC);Contraceptive Vaginal Ring (CVR)
50 GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition Active, not recruiting NCT03616509 Phase 4 Growth hormone;Placebo

Search NIH Clinical Center for Insulin-Like Growth Factor I

Sources

Genetic Tests for Insulin-Like Growth Factor I

About this section

Genetic tests related to Insulin-Like Growth Factor I:

# Genetic test Affiliating Genes
1 Insulin-Like Growth Factor I Deficiency 29 IGF1
2 Insulin-Like Growth Factor 1 Resistance to 29 IGF1R
Sources

Anatomical Context for Insulin-Like Growth Factor I

About this section

MalaCards organs/tissues related to Insulin-Like Growth Factor I:

41
Breast, Bone, Prostate, Liver, Pituitary, Brain, Endothelial
Sources

Publications for Insulin-Like Growth Factor I

About this section

Articles related to Insulin-Like Growth Factor I:

(show top 50) (show all 3138)
# Title Authors Year
1
Associations of insulin-like growth factor-I and insulin-like growth factor binding protein-3 with bone quality in the general adult population. ( 29498081 )
2018
2
Factors correlated with serum insulin-like growth factor-I levels in health check-up subjects. ( 29395967 )
2018
3
Pre-diagnostic circulating insulin-like growth factor-I and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition. ( 29971779 )
2018
4
The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. ( 29724795 )
2018
5
Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression. ( 29330502 )
2018
6
Deficiency of liver-derived insulin-like growth factor-I (IGF-I) does not interfere with the skin wound healing rate. ( 29534073 )
2018
7
Correlation of Insulin-Like Growth Factor-I and -II Concentrations at Birth Measured by Mass Spectrometry and Growth from Birth to Two Months. ( 29402777 )
2018
8
For Debate: Combination Growth Hormone and Insulin-Like Growth Factor-I Therapy for Childhood Growth Disorders: Prime Time or Too Much Dime? ( 29493124 )
2018
9
Bioresponsive release of insulin-like growth factor-I from its PEGylated conjugate. ( 29634992 )
2018
10
Influence of ad libitum milk replacer feeding and butyrate supplementation on the systemic and hepatic insulin-like growth factor I and its binding proteins in Holstein calves. ( 29248211 )
2018
11
New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor. ( 29744034 )
2018
12
Fucoidan downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells. ( 29328495 )
2018
13
Association of body weight gain with muscle, fat, and liver expression levels of growth hormone receptor, insulin-like growth factor I, and beta-adrenergic receptor mRNAs in steers. ( 29730537 )
2018
14
Intermittent hypoxia suppression of growth hormone and insulin-like growth factor-I in the neonatal rat liver. ( 29544682 )
2018
15
Insulin-like Growth Factor I Receptor: A Novel Target for Hepatocellular Carcinoma Gene Therapy. ( 30360707 )
2018
16
A longitudinal study of serum insulin-like growth factor-I levels over 6 years in a large cohort of children and adolescents with type 1 diabetes mellitus: A marker reflecting diabetic retinopathy. ( 29663652 )
2018
17
Relationships of plasma insulin-like peptide 3, testosterone, inhibin, and insulin-like growth factor-I concentrations with scrotal circumference and testicular weight in Japanese Black beef bull calves. ( 29984734 )
2018
18
Synergistic effects of tumor necrosis factor-α and insulin-like growth factor-I on survival of human trophoblast-derived BeWo cell line. ( 30005335 )
2018
19
Assessment using serum insulin-like growth factor-I and bone mineral density is useful for detecting prevalent vertebral fractures in patients with type 2 diabetes mellitus. ( 30030585 )
2018
20
Expression of insulin-like growth factor I and its receptor in the liver of children with biopsy-proven NAFLD. ( 30063751 )
2018
21
Circulating insulin-like growth factor I modulates mood and is a biomarker of vulnerability to stress: from mouse to man. ( 30068974 )
2018
22
Altered levels of circulating insulin-like growth factor I (IGF-I) following ischemic stroke are associated with outcome - a prospective observational study. ( 30081862 )
2018
23
Effect of insulin treatment on circulating insulin-like growth factor I and IGF-binding proteins in cats with diabetes mellitus. ( 30112786 )
2018
24
Insulin-like growth factor I receptor regulates the radiation-induced G2/M checkpoint in HeLa cells. ( 30119887 )
2018
25
Insulin-Like Growth Factor-I as an Effector Element of the Cytokine IL-4 in the Development of a Leishmania major Infection. ( 30150896 )
2018
26
Circulating insulin-like growth factor I in relation to melanoma risk in the European Prospective Investigation into Cancer and Nutrition. ( 30191956 )
2018
27
Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. ( 30215690 )
2018
28
Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells. ( 30229539 )
2018
29
Growth hormone and Insulin-like growth factor-I (IGF-I) modulate the expression of L-type amino acid transporters in the muscles of spontaneous dwarf rats and L6 and C2C12 myocytes. ( 30273774 )
2018
30
Insulin-like growth factor-I is required to maintain muscle volume in adult mice. ( 30324536 )
2018
31
Standardization of Growth Hormone and Insulin-like Growth Factor-I Measurement. ( 30378780 )
2018
32
The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy. ( 30385883 )
2018
33
Insulin-Like Growth Factor I Regulation and Its Actions in Skeletal Muscle. ( 30549022 )
2018
34
Serum insulin-like growth factor-I levels are associated with improved white matter recovery after traumatic brain injury. ( 28574152 )
2017
35
Insulin-like growth factor-I induces chemoresistence to docetaxel by inhibiting miR-143 in human prostate cancer. ( 29291019 )
2017
36
Feeling misguided: a comment on the US guidelines on growth hormone and insulin-like growth factor-I treatment in children and adolescents. ( 28604412 )
2017
37
A Coordinated Action of Blood-Borne and Brain Insulin-Like Growth Factor I in the Response to Traumatic Brain Injury. ( 28449086 )
2017
38
Serum reference value of two potential doping candidates-myostatin and insulin-like growth factor-I in the healthy young male. ( 28077934 )
2017
39
Effect of pre- and postpartum supplementation with lipid-encapsulated conjugated linoleic acid on reproductive performance and the growth hormone-insulin-like growth factor-I axis in multiparous high-producing dairy cows. ( 28456404 )
2017
40
Rejuvenating Effect of Long-Term Insulin-Like Growth Factor-I Gene Therapy in the Hypothalamus of Aged Rats with Dopaminergic Dysfunction. ( 28673122 )
2017
41
Prediagnostic circulating concentrations of plasma insulin-like growth factor-I and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition. ( 27870006 )
2017
42
Addition of insulin-like growth factor I to the maturation medium of bovine oocytes subjected to heat shock: effects on the production of reactive oxygen species, mitochondrial activity and oocyte competence. ( 28445838 )
2017
43
The role of insulin-like growth factor I-II receptor on development of pleomorphic adenoma. ( 28625007 )
2017
44
First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I. ( 28110155 )
2017
45
Insulin-like growth factor I and its binding protein-3 are regulators of lactation and maternal responsiveness. ( 28611445 )
2017
46
Feed restriction and insulin-like growth factor-I (IGF-I) affect the oocyte maturation in matrinxAL Brycon amazonicus. ( 27928979 )
2017
47
The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver. ( 28678199 )
2017
48
Insulin-like growth factor I reduces the occurrence of necrotizing enterocolitis by reducing inflammatory response and protecting intestinal mucosal barrier in neonatal rats model. ( 29131241 )
2017
49
Reference ranges for serum insulin-like growth factor I (IGF-I) in healthy Chinese adults. ( 28976993 )
2017
50
Interaction of insulin-like growth factor-I and insulin resistance-related genetic variants with lifestyle factors on postmenopausal breast cancer risk. ( 28478612 )
2017
Sources

Variations for Insulin-Like Growth Factor I

About this section

UniProtKB/Swiss-Prot genetic disease variations for Insulin-Like Growth Factor I:

75
# Symbol AA change Variation ID SNP ID
1 IGF1R p.Arg138Gln VAR_034891 rs121912426
2 IGF1R p.Lys145Asn VAR_034892 rs121912427
3 IGF1R p.Arg739Gln VAR_034895 rs121912429
4 IGF1R p.Asn359Tyr VAR_076247
5 IGF1R p.Tyr865Cys VAR_076248
6 IGF1R p.Arg1256Ser VAR_076249
7 IGF1R p.Arg1337Cys VAR_076250 rs141802822

ClinVar genetic disease variations for Insulin-Like Growth Factor I:

6 (show top 50) (show all 660)
# Gene Variation Type Significance SNP ID Assembly Location
1 IGF1 IGF1, EX4-5DEL deletion Pathogenic
2 IGF1 IGF1, MUTATION IN POLYADENYLATION SIGNAL, T-A single nucleotide variant Pathogenic
3 IGF1 NM_001111284.1(IGF1): c.226G> A (p.Val76Met) single nucleotide variant Pathogenic rs121912430 GRCh37 Chromosome 12, 102813415: 102813415
4 IGF1 NM_001111284.1(IGF1): c.226G> A (p.Val76Met) single nucleotide variant Pathogenic rs121912430 GRCh38 Chromosome 12, 102419637: 102419637
5 IGF1R NM_000875.4(IGF1R): c.413G> A (p.Arg138Gln) single nucleotide variant protective rs121912426 GRCh37 Chromosome 15, 99251109: 99251109
6 IGF1R NM_000875.4(IGF1R): c.413G> A (p.Arg138Gln) single nucleotide variant protective rs121912426 GRCh38 Chromosome 15, 98707880: 98707880
7 IGF1R NM_000875.4(IGF1R): c.435A> C (p.Lys145Asn) single nucleotide variant protective rs121912427 GRCh37 Chromosome 15, 99251131: 99251131
8 IGF1R NM_000875.4(IGF1R): c.435A> C (p.Lys145Asn) single nucleotide variant protective rs121912427 GRCh38 Chromosome 15, 98707902: 98707902
9 IGF1R NM_000875.4(IGF1R): c.265C> T (p.Arg89Ter) single nucleotide variant protective rs121912428 GRCh37 Chromosome 15, 99250961: 99250961
10 IGF1R NM_000875.4(IGF1R): c.265C> T (p.Arg89Ter) single nucleotide variant protective rs121912428 GRCh38 Chromosome 15, 98707732: 98707732
11 IGF1R NM_000875.4(IGF1R): c.2216G> A (p.Arg739Gln) single nucleotide variant protective rs121912429 GRCh37 Chromosome 15, 99465391: 99465391
12 IGF1R NM_000875.4(IGF1R): c.2216G> A (p.Arg739Gln) single nucleotide variant protective rs121912429 GRCh38 Chromosome 15, 98922162: 98922162
13 IGF1R NM_000875.4(IGF1R): c.1532G> A (p.Arg511Gln) single nucleotide variant Uncertain significance rs33958176 GRCh37 Chromosome 15, 99454613: 99454613
14 IGF1R NM_000875.4(IGF1R): c.1532G> A (p.Arg511Gln) single nucleotide variant Uncertain significance rs33958176 GRCh38 Chromosome 15, 98911384: 98911384
15 IGF1 NM_001111283.2(IGF1): c.292C> T (p.Arg98Trp) single nucleotide variant Pathogenic rs587779350 GRCh37 Chromosome 12, 102813397: 102813397
16 IGF1 NM_001111283.2(IGF1): c.292C> T (p.Arg98Trp) single nucleotide variant Pathogenic rs587779350 GRCh38 Chromosome 12, 102419619: 102419619
17 IGF1R NM_000875.4(IGF1R): c.2298C> T (p.Thr766=) single nucleotide variant Benign rs3743262 GRCh37 Chromosome 15, 99465473: 99465473
18 IGF1R NM_000875.4(IGF1R): c.2298C> T (p.Thr766=) single nucleotide variant Benign rs3743262 GRCh38 Chromosome 15, 98922244: 98922244
19 IGF1R NM_000875.4(IGF1R): c.2700C> T (p.Asn900=) single nucleotide variant Benign/Likely benign rs56400113 GRCh37 Chromosome 15, 99467831: 99467831
20 IGF1R NM_000875.4(IGF1R): c.2700C> T (p.Asn900=) single nucleotide variant Benign/Likely benign rs56400113 GRCh38 Chromosome 15, 98924602: 98924602
21 IGF1R NM_000875.4(IGF1R): c.3129G> A (p.Glu1043=) single nucleotide variant Benign rs2229765 GRCh37 Chromosome 15, 99478225: 99478225
22 IGF1R NM_000875.4(IGF1R): c.3129G> A (p.Glu1043=) single nucleotide variant Benign rs2229765 GRCh38 Chromosome 15, 98934996: 98934996
23 IGF1R NM_000875.4(IGF1R): c.225C> T (p.Phe75=) single nucleotide variant Conflicting interpretations of pathogenicity rs55770488 GRCh37 Chromosome 15, 99250921: 99250921
24 IGF1R NM_000875.4(IGF1R): c.225C> T (p.Phe75=) single nucleotide variant Conflicting interpretations of pathogenicity rs55770488 GRCh38 Chromosome 15, 98707692: 98707692
25 IGF1R NM_000875.4(IGF1R): c.1950G> T (p.Arg650=) single nucleotide variant Conflicting interpretations of pathogenicity rs56294552 GRCh37 Chromosome 15, 99459314: 99459314
26 IGF1R NM_000875.4(IGF1R): c.1950G> T (p.Arg650=) single nucleotide variant Conflicting interpretations of pathogenicity rs56294552 GRCh38 Chromosome 15, 98916085: 98916085
27 IGF1R NM_001291858.1(IGF1R): c.3184-2A> T single nucleotide variant Likely pathogenic rs886042346 GRCh37 Chromosome 15, 99478543: 99478543
28 IGF1R NM_001291858.1(IGF1R): c.3184-2A> T single nucleotide variant Likely pathogenic rs886042346 GRCh38 Chromosome 15, 98935314: 98935314
29 IGF1R NM_000875.4(IGF1R): c.4038C> T (p.Tyr1346=) single nucleotide variant Benign/Likely benign rs17847203 GRCh37 Chromosome 15, 99500605: 99500605
30 IGF1R NM_000875.4(IGF1R): c.4038C> T (p.Tyr1346=) single nucleotide variant Benign/Likely benign rs17847203 GRCh38 Chromosome 15, 98957376: 98957376
31 IGF1 NM_000618.4(IGF1): c.*4421_*4422insT insertion Uncertain significance rs886048870 GRCh38 Chromosome 12, 102398085: 102398086
32 IGF1 NM_000618.4(IGF1): c.*6433G> C single nucleotide variant Likely benign rs5742714 GRCh38 Chromosome 12, 102396074: 102396074
33 IGF1 NM_000618.4(IGF1): c.*6433G> C single nucleotide variant Likely benign rs5742714 GRCh37 Chromosome 12, 102789852: 102789852
34 IGF1 NM_000618.4(IGF1): c.*5533C> T single nucleotide variant Uncertain significance rs566519887 GRCh38 Chromosome 12, 102396974: 102396974
35 IGF1 NM_000618.4(IGF1): c.*5533C> T single nucleotide variant Uncertain significance rs566519887 GRCh37 Chromosome 12, 102790752: 102790752
36 IGF1 NM_000618.4(IGF1): c.*5449G> A single nucleotide variant Uncertain significance rs569070910 GRCh38 Chromosome 12, 102397058: 102397058
37 IGF1 NM_000618.4(IGF1): c.*5449G> A single nucleotide variant Uncertain significance rs569070910 GRCh37 Chromosome 12, 102790836: 102790836
38 IGF1 NM_000618.4(IGF1): c.*5187A> G single nucleotide variant Uncertain significance rs886048863 GRCh38 Chromosome 12, 102397320: 102397320
39 IGF1 NM_000618.4(IGF1): c.*5187A> G single nucleotide variant Uncertain significance rs886048863 GRCh37 Chromosome 12, 102791098: 102791098
40 IGF1 NM_000618.4(IGF1): c.*5079T> C single nucleotide variant Uncertain significance rs886048864 GRCh38 Chromosome 12, 102397428: 102397428
41 IGF1 NM_000618.4(IGF1): c.*5079T> C single nucleotide variant Uncertain significance rs886048864 GRCh37 Chromosome 12, 102791206: 102791206
42 IGF1 NM_000618.4(IGF1): c.*4980T> C single nucleotide variant Uncertain significance rs886048865 GRCh38 Chromosome 12, 102397527: 102397527
43 IGF1 NM_000618.4(IGF1): c.*4980T> C single nucleotide variant Uncertain significance rs886048865 GRCh37 Chromosome 12, 102791305: 102791305
44 IGF1 NM_000618.4(IGF1): c.*4940C> A single nucleotide variant Uncertain significance rs886048866 GRCh38 Chromosome 12, 102397567: 102397567
45 IGF1 NM_000618.4(IGF1): c.*4940C> A single nucleotide variant Uncertain significance rs886048866 GRCh37 Chromosome 12, 102791345: 102791345
46 IGF1 NM_000618.4(IGF1): c.*4540C> T single nucleotide variant Uncertain significance rs184498533 GRCh37 Chromosome 12, 102791745: 102791745
47 IGF1 NM_000618.4(IGF1): c.*4540C> T single nucleotide variant Uncertain significance rs184498533 GRCh38 Chromosome 12, 102397967: 102397967
48 IGF1 NM_000618.4(IGF1): c.*4421_*4422insT insertion Uncertain significance rs886048870 GRCh37 Chromosome 12, 102791863: 102791864
49 IGF1 NM_000618.4(IGF1): c.*3933G> C single nucleotide variant Uncertain significance rs886048874 GRCh37 Chromosome 12, 102792352: 102792352
50 IGF1 NM_000618.4(IGF1): c.*3933G> C single nucleotide variant Uncertain significance rs886048874 GRCh38 Chromosome 12, 102398574: 102398574
Sources

Expression for Insulin-Like Growth Factor I

About this section
Search GEO for disease gene expression data for Insulin-Like Growth Factor I.
Sources

Pathways for Insulin-Like Growth Factor I

About this section

Pathways related to Insulin-Like Growth Factor I according to KEGG:

37
# Name Kegg Source Accession
1 PI3K-Akt signaling pathway hsa04151
2 Oocyte meiosis hsa04114
3 Focal adhesion hsa04510
4 Adherens junction hsa04520
5 Long-term depression hsa04730
6 Progesterone-mediated oocyte maturation hsa04914

Pathways related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show top 50) (show all 108)
# Super pathways Score Top Affiliating Genes
1
Apoptotic Pathways in Synovial Fibroblasts 64
Show member pathways
 13.96 AKT1 AKT2 GH1 IGF1 IGF1R IGF2
2
ERK Signaling 64
Show member pathways
 13.95 AKT1 AKT2 GH1 IGF1 IGF1R IGF2
3
Metabolism of proteins 66
Show member pathways
 13.89 GH1 IGF1 IGF2 IGFBP1 IGFBP2 IGFBP3
4
GPCR Pathway 64
Show member pathways
 13.81 AKT1 AKT2 GH1 IGF1 IGF1R IGF2
5
TGF-Beta Pathway 64
Show member pathways
 13.55 AKT1 AKT2 GH1 GHR IGF1 IGF1R
6
Akt Signaling 64
Show member pathways
 13.5 AKT1 AKT2 GH1 IGF1 IGF1R IGF2
7
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13.39 AKT1 AKT2 IGF1 IGF2 ITGA6 ITGAV
8
IL-2 Pathway 64
Show member pathways
 13.31 AKT1 AKT2 GH1 GHR IGF1 IGF1R
9
Phospholipase-C Pathway 64
Show member pathways
 13.18 AKT1 AKT2 GH1 IGF1 IGF1R IGF2
10
p70S6K Signaling 64
Show member pathways
 13.16 AKT1 GH1 IGF1 IGF1R IGF2 INS
11
Actin Nucleation by ARP-WASP Complex 64
Show member pathways
 13.09 IGF1 IGF1R IGF2 INSR ITGA6 ITGAV
12
TNFR1 Pathway 64
Show member pathways
 13.03 AKT1 AKT2 IGF1 IGF1R IGF2 IRS1
13
Focal Adhesion 1 37
Show member pathways
 13.01 AKT1 AKT2 IGF1 IGF1R ITGA6 ITGAV
14
Endometrial cancer 37
Show member pathways
 12.96 AKT1 AKT2 IGF1 IGF1R INS IRS1
15
Pathways in cancer 37
12.96 AKT1 AKT2 IGF1 IGF1R IGF2 ITGA6
16
Beta-Adrenergic Signaling 64
Show member pathways
 12.93 AKT1 INS INSR IRS1 ITGA6 ITGAV
17
Apoptosis Modulation and Signaling 1
Show member pathways
 12.88 AKT1 AKT2 IGF1 IGF1R IGF2
18
MAPK signaling pathway 37 1
12.88 AKT1 AKT2 IGF1 IGF1R IGF2 INS
19
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 12.88 AKT1 AKT2 GH1 GHR IGF1 IGF1R
20
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 12.85 AKT1 AKT2 INS INSR IRS1
21
Ras signaling pathway 37
Show member pathways
 12.85 AKT1 AKT2 IGF1 IGF1R IGF2 INS
22
Glioma 37
Show member pathways
 12.84 AKT1 AKT2 IGF1 IGF1R IRS1
23
Gastric cancer 37
Show member pathways
 12.84 AKT1 AKT2 IGF1 IGF1R IGF2
24
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.81 AKT1 AKT2 IGF1 IGF1R IGF2 INSR
25
PI3K-Akt signaling pathway 37
Show member pathways
 12.81 AKT1 AKT2 GH1 GHR IGF1 IGF1R
26
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.8 AKT1 AKT2 INS INSR IRS1
27
Vascular smooth muscle contraction 37
Show member pathways
 12.8 AKT1 AKT2 INS INSR IRS1
28
Development Dopamine D2 receptor transactivation of EGFR 22
Show member pathways
 12.67 AKT1 AKT2 IGF1 IGF1R IRS1
29
Myometrial Relaxation and Contraction Pathways 1
Show member pathways
 12.66 IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6
30
Angiopoietin Like Protein 8 Regulatory Pathway 1
Show member pathways
 12.65 AKT1 AKT2 IGF1R INS INSR IRS1
31
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.63 AKT1 AKT2 IGF1 IGF1R INS INSR
32
Prolactin Signaling Pathway 1 37
Show member pathways
 12.58 AKT1 AKT2 GH1 INS IRS1
33
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.56 AKT1 AKT2 IGF1 IGF1R INS INSR
34
Apoptosis Pathway 72
Show member pathways
 12.54 AKT1 AKT2 IGF1R INSR ITGAV
35
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.52 GH1 IGF1 IGF1R IGF2 INSR ITGA6
36
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.5 AKT1 AKT2 GH1 GHR IGF1R
37
Phospholipase D signaling pathway 37
Show member pathways
 12.47 AKT1 AKT2 INS INSR
38
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.47 AKT1 AKT2 ITGAV ITGB3
39
Oocyte meiosis 37
Show member pathways
 12.46 AKT1 AKT2 IGF1 IGF1R INS
40
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.46 AKT1 AKT2 IGF1 IGF1R INSR IRS1
41
Glucose / Energy Metabolism 4
12.46 AKT1 AKT2 IGF1R IGFBP1 IGFBP2 IGFBP3
42
MET promotes cell motility 66
Show member pathways
 12.42 AKT1 IRS1 ITGA6 ITGAV
43
Proteoglycans in cancer 37
12.39 AKT1 AKT2 IGF1 IGF1R IGF2 ITGAV
44
Apoptosis and survival Caspase cascade 22
Show member pathways
 12.38 AKT1 AKT2 IGF1 IGF1R IRS1
45
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.36 AKT1 GH1 IGF1 IGF1R IGF2
46
AMPK Enzyme Complex Pathway 64
Show member pathways
 12.34 AKT1 AKT2 INS INSR IRS1
47
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.34 AKT1 AKT2 IGF1R INSR ITGA6 ITGAV
48
VEGF Signaling Pathway 61 67
Show member pathways
 12.31 AKT1 AKT2 ITGAV ITGB3
49
Dilated cardiomyopathy (DCM) 37
Show member pathways
 12.3 IGF1 ITGA6 ITGAV ITGB3
50
MicroRNAs in cardiomyocyte hypertrophy 1
Show member pathways
 12.26 AKT1 AKT2 IGF1 IGF1R
Sources

GO Terms for Insulin-Like Growth Factor I

About this section

Cellular components related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.88 IGFBP1 IGFBP3 IGFBP4 IGFBP5 INS
2 receptor complex GO:0043235 9.83 GHR IGF1R INSR ITGB3
3 ruffle membrane GO:0032587 9.71 AKT2 ITGAV ITGB3
4 integrin complex GO:0008305 9.63 ITGA6 ITGAV ITGB3
5 alphav-beta3 integrin-HMGB1 complex GO:003586